Latest News and Press Releases

STOCKHOLM, SVERIGE 1 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Dilafors läkemedelskandidat tafoxiparin i en nyligen genomförd fas 2b-studie visat...

STOCKHOLM, SWEDEN 1 June 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Dilafor has concluded a phase 2b study with its drug candidate tafoxiparin...

STOCKHOLM, SVERIGE 21 maj 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Umecrine Cognition förbereder en notering på Nasdaq First North Growth Market under...

STOCKHOLM, SWEDEN 21 May 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Umecrine Cognition is preparing a listing on Nasdaq First North Growth...

STOCKHOLM, SVERIGE 12 maj 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att bolagets portföljbolag OssDsign AB genomfört en framgångsrik nyemission av aktier med...

STOCKHOLM, SWEDEN – May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential...

STOCKHOLM, SVERIGE – 5 maj 2021. Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) har den 5 maj 2021 hållit sin årsstämma. Med anledning av den fortsatta spridningen av...

STOCKHOLM, SWEDEN – May 5, 2021. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 5, 2021. Due to the continued spread of the...

STOCKHOLM – den 29 april 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari - mars 2021. Den fulla rapporten är tillgänglig på bolagets hemsida. ...

STOCKHOLM – 29 April 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2021. The full report is available on the Company's website. “In...